v3.26.1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Disaggregation of Income Statement Expenses
This following table presents segment operation results for the three months ended March 31, 2026 and 2025:
Three Months Ended
March 31,
20262025
Operating expenses:
Research and development - external costs (1)
$256,432 $103,806 
Research and development - internal costs (2)
56,347 44,328 
General and administrative
33,071 32,659 
Total operating expenses
$345,850 $180,793 
Total other income, net
25,228 40,075 
Net loss
$320,622 $140,718 
____________________________________________________________
(1)Research and development - external costs consist primarily of product and clinical development, research, facility, depreciation, professional and consulting services expenses attributed to the research and development departments.
(2)Research and development - internal costs consist of internal employee costs including stock-based compensation expenses.